NasdaqGM - Nasdaq Real Time Price USD

Aquestive Therapeutics, Inc. (AQST)

Compare
4.9500 -0.0800 (-1.59%)
At close: October 21 at 4:00 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
58,360.0000
50,583.0000
47,680.0000
50,832.0000
45,849.0000
--
Cost of Revenue
18,392.0000
20,831.0000
19,386.0000
14,989.0000
12,964.0000
--
Gross Profit
39,968.0000
29,752.0000
28,294.0000
35,843.0000
32,885.0000
--
Operating Expense
55,158.0000
44,854.0000
70,360.0000
70,522.0000
75,778.0000
--
Operating Income
-15,190.0000
-15,102.0000
-42,066.0000
-34,679.0000
-42,893.0000
--
Net Non Operating Interest Income Expense
-9,539.0000
8,859.0000
-12,344.0000
-22,038.0000
-12,890.0000
--
Other Income Expense
--
-1,382.0000
--
-13,822.0000
--
-4,896.0000
Pretax Income
-25,758.0000
-7,625.0000
-54,410.0000
-70,539.0000
-55,783.0000
--
Tax Provision
-39.0000
245.0000
--
--
--
--
Net Income Common Stockholders
-25,719.0000
-7,870.0000
-54,410.0000
-70,539.0000
-55,783.0000
--
Diluted NI Available to Com Stockholders
-25,719.0000
-7,870.0000
-54,410.0000
-70,539.0000
-55,783.0000
--
Basic EPS
-0.36
-0.13
-1.12
-1.85
-1.66
--
Diluted EPS
-0.36
-0.13
-1.12
-1.85
-1.66
--
Basic Average Shares
74,140.0460
61,255.8640
48,734.3770
38,077.6600
33,651.1270
--
Diluted Average Shares
74,140.0460
61,255.8640
48,734.3770
38,077.6600
33,651.1270
--
Total Operating Income as Reported
-15,190.0000
-15,102.0000
-42,066.0000
-34,679.0000
-42,893.0000
--
Total Expenses
73,550.0000
65,685.0000
89,746.0000
85,511.0000
88,742.0000
--
Net Income from Continuing & Discontinued Operation
-25,719.0000
-7,870.0000
-54,410.0000
-70,539.0000
-55,783.0000
--
Normalized Income
-24,691.5580
-6,532.5004
-54,410.0000
-56,733.5864
-55,783.0000
--
Interest Income
3,403.0000
16,321.0000
99.0000
423.0000
132.0000
--
Interest Expense
12,942.0000
7,462.0000
12,443.0000
22,461.0000
13,022.0000
--
Net Interest Income
-9,539.0000
8,859.0000
-12,344.0000
-22,038.0000
-12,890.0000
--
EBIT
-12,816.0000
-163.0000
-41,967.0000
-48,078.0000
-42,761.0000
--
EBITDA
-11,673.0000
1,182.0000
-39,580.0000
-45,114.0000
-39,318.0000
--
Reconciled Cost of Revenue
18,392.0000
20,831.0000
19,386.0000
14,989.0000
12,964.0000
--
Reconciled Depreciation
1,143.0000
1,345.0000
2,387.0000
2,964.0000
3,443.0000
--
Net Income from Continuing Operation Net Minority Interest
-25,719.0000
-7,870.0000
-54,410.0000
-70,539.0000
-55,783.0000
--
Total Unusual Items Excluding Goodwill
-1,029.0000
-1,382.0000
--
-13,822.0000
--
--
Total Unusual Items
-1,029.0000
-1,382.0000
--
-13,822.0000
--
--
Normalized EBITDA
-10,644.0000
2,564.0000
-39,580.0000
-31,292.0000
-39,318.0000
--
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
--
--
Tax Effect of Unusual Items
-1.5580
-44.5004
--
-16.5864
--
--
12/31/2019 - 7/25/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers